Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The global active pharmaceutical ingredients market size was worth USD 239.18 billion in 2024 and is expected to reach around USD 368.49 billion by 2033, with a noteworthy CAGR of 5.64% from 2023 to ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

SNS Insider Reports: Increasing Awareness, Advancements in Drug Development, and government Initiatives fuel market Growth at a CAGR of 4.06% from 2024-2032 ...